CytoDyn Receives FDA Clearance for Its First Non-HIV Indication for PRO 140

Dec 14, 2015 8:30am EST

Eleven HIV Patients Successfully Reach One Year of Full Virologic Suppression in PRO 140 Monotherapy Phase 2b Extension Study

Dec 01, 2015 8:30am EST

CytoDyn Hires New Senior Vice President of Manufacturing for PRO 140

Nov 24, 2015 6:30am EST

CytoDyn Announces Investment Community Conference Call

Nov 18, 2015 6:30am EST

CytoDyn Injects First Patient in Its Current Phase 3 Study

Oct 22, 2015 6:30am EDT

CytoDyn Files an IND and Full Protocol for Phase 2 Study in GvHD

Oct 20, 2015 6:30am EDT

HIV Patients Successfully Reach One Year of Virologic Suppression in PRO 140 Monotherapy Study

Sep 21, 2015 6:30am EDT

Cytodyn Initiates First Clinical Site for Phase 3 Trial of PRO 140

Aug 05, 2015 4:01pm EDT

CytoDyn Completes Qualification of PRO 140 Material for Phase 3

Jul 29, 2015 6:30am EDT

Evidence of HIV Suppression With PRO 140 Monotherapy Reaching Nearly 11 Months

Jul 15, 2015 6:30am EDT